Alder BioPharma (ALDR) Misses Q3 EPS by 11c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. XYZ
9. SPY
10. FISV

Go back to Alder BioPharma (ALDR) Misses Q3 EPS by 11c

Alder BioPharmaceuticals Reports Third Quarter 2015 Financial and Operating Results

November 5, 2015 4:06 PM EST

Initiated First of Two Pivotal Clinical Trials Planned to Support BLA Filing for ALD403 in Migraine Prevention

Two ALD403 Data Readouts Anticipated in 1Q16

BOTHELL, Wash., Nov. 05, 2015 (GLOBE NEWSWIRE) --  Alder BioPharmaceuticals, Inc. (Alder) (NASDAQ: ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics for the treatment of migraine, Cushings disease, Congenital Adrenal Hyperplasia and autoimmune and inflammatory diseases, today provided recent corporate highlights and reported its financial results for the third quarter ended September 30, 2015.

We continue to execute on our accelerated... More